# Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

> **NCT00478205** · PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 1467 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Aricept (donepezil SR 23 mg)
- **DRUG:** Aricept (donepezil IR 10 mg)

## Key facts

- **NCT ID:** NCT00478205
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2009-06
- **Final completion:** —
- **Target enrollment:** 1467 (ACTUAL)
- **Last updated:** 2014-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00478205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00478205, "Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00478205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*